Aurobindo Pharma Limited

BSE:524804 Stock Report

Market Cap: ₹721.2b

Aurobindo Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

BSE:524804 Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
29 Feb 24Sell₹1,022,000P.S. PavankumarIndividual1,000₹1,022.00
27 Feb 24Sell₹2,094,775Chandrasekhar KandatiIndividual2,000₹1,047.39
21 Feb 24Sell₹1,025,000P.S. PavankumarIndividual1,000₹1,025.00
19 Feb 24Sell₹5,242,300K. NagarajuIndividual5,000₹1,048.46
16 Feb 24Sell₹3,923,040Roopak SawhneyIndividual3,880₹1,011.09
15 Feb 24Sell₹35,598,849K. BharathiIndividual35,000₹1,017.11
15 Feb 24Sell₹5,100,000A. Rama RaoIndividual5,000₹1,020.00
14 Feb 24Sell₹1,277,900Gita RaoIndividual1,300₹983.00
13 Feb 24Sell₹2,054,000S. ReddyIndividual2,000₹1,027.00
29 Dec 23Sell₹9,720,146P. SashikumaranIndividual9,000₹1,080.02
29 Dec 23Sell₹1,079,000S. ReddyIndividual1,000₹1,079.00
29 Dec 23Sell₹4,310,000Akkiraju MohanIndividual4,000₹1,077.50
29 Dec 23Sell₹1,082,600K. ReddyIndividual1,000₹1,082.60
28 Dec 23Sell₹16,074,150S. ReddyIndividual15,000₹1,071.61

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of 524804?
Owner TypeNumber of SharesOwnership Percentage
State or Government909,9840.157%
General Public75,475,24413%
Individual Insiders88,911,75415.3%
Institutions197,361,41934%
Private Companies218,143,22237.6%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 80.43% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
34.5%
Penaka Family Trust
200,136,929₹248.5b-0.9%no data
5.61%
Kambam Reddy
32,604,498₹40.5b-0.19%no data
4.74%
ICICI Prudential Asset Management Company Limited
27,540,489₹34.2b11.8%0.6%
4.42%
HDFC Asset Management Company Limited
25,646,956₹31.8b0.82%0.67%
3.6%
quant Money Managers Ltd.
20,923,424₹26.0b9.15%2.58%
3.45%
Kambam Reddy
20,062,852₹24.9b-0.92%no data
3.07%
Penaka Venkata Reddy
17,833,646₹22.1b-0.92%no data
2.47%
Meenakshi Sivakumaran
14,357,432₹17.8b-0.92%no data
2.34%
Mirae Asset Global Investments Co., Ltd.
13,565,618₹16.8b-13.8%0.17%
2.08%
Life Insurance Corporation of India, Asset Management Arm
12,072,348₹15.0b-26%0.1%
1.84%
The Vanguard Group, Inc.
10,662,246₹13.2b0.22%no data
1.73%
BlackRock, Inc.
10,064,531₹12.5b-2.69%no data
1.63%
BNP Paribas Arbitrage Sa, Asset Management Arm
9,463,002₹11.8b0%0.12%
1.13%
Invesco Ltd.
6,536,299₹8.1b0%0.03%
1.09%
Trident Chemphar Limited
6,306,285₹7.8b-0.92%no data
1.06%
AXIS Clinicals Limited
6,175,964₹7.7b-0.92%no data
0.95%
RPR Sons Advisors Private Limited
5,524,044₹6.9b0%no data
0.93%
Dimensional Fund Advisors LP
5,403,240₹6.7b0.79%0.01%
0.76%
Nippon Life India Asset Management Limited
4,418,758₹5.5b12.1%0.14%
0.67%
Bandhan AMC Limited
3,889,454₹4.8b1.56%0.73%
0.64%
Tata Asset Management Limited
3,723,332₹4.6b-4.43%0.44%
0.5%
Norges Bank Investment Management
2,896,672₹3.6b0%no data
0.45%
SBI Funds Management Limited
2,619,988₹3.3b29.3%0.04%
0.41%
Motilal Oswal Asset Management Company Limited
2,390,363₹3.0b0.38%0.32%
0.4%
Kotak Mahindra Asset Management Company Limited
2,337,972₹2.9b-9.22%0.1%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 13:56
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aurobindo Pharma Limited is covered by 54 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Meeta ShettyAsian Markets Securities Private Limited
Kamlesh KotakAsian Markets Securities Private Limited
Harith AhamedAvendus Spark